

Lupin partners with TTP for soft-mist inhalation tech platform

02 December 2021 | News

To complement Lupin's portfolio of complex inhalation products



Lupin has entered into an agreement with TTP (The Technology Partnership) to acquire the exclusive worldwide rights to develop, manufacture and commercialise inhalation products using TTP's soft-mist inhalation technology platform. By leveraging this technology, Lupin expects to provide healthcare professionals with alternative solutions for delivering affordable inhaled medicines to patients across the globe.

Soft-mist inhalation (SMI) technology allows for the delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants. The individual doses are delivered using a precisely engineered nozzle system to produce a slow-moving and long-sustaining aerosol cloud. Mumbai-based pharma firm Lupin anticipates applications across respiratory care.

Lupin and TTP will jointly develop the device. Lupin will commercially manufacture the device through its network of in-house and external manufacturing locations. Lupin will also develop and manufacture formulations to be delivered through the device, obtain the necessary regulatory approvals, and commercialise the products globally.